NYSE:TARO - Taro Pharmaceutical Industries Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$107.83 +0.27 (+0.25 %)
(As of 03/22/2019 06:25 AM ET)
Previous Close$107.56
Today's Range$107.15 - $109.00
52-Week Range$76.93 - $121.23
Volume51,816 shs
Average Volume68,003 shs
Market Capitalization$4.25 billion
P/E Ratio17.45
Dividend YieldN/A
Beta0.52
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-4847-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$661.91 million
Cash Flow$6.7352 per share
Book Value$56.06 per share

Profitability

Net Income$211.15 million

Miscellaneous

Employees1,490
Market Cap$4.25 billion
Next Earnings Date5/16/2019 (Estimated)
OptionableOptionable

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How often does Taro Pharmaceutical Industries pay dividends? What is the dividend yield for Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries declared a dividend on Monday, November 5th. Shareholders of record on Tuesday, December 11th will be paid a dividend of $12.81 per share on Friday, December 28th. The ex-dividend date of this dividend is Monday, December 10th. View Taro Pharmaceutical Industries' Dividend History.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) released its quarterly earnings data on Wednesday, February, 6th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.45. The business earned $176.38 million during the quarter, compared to the consensus estimate of $174.70 million. Taro Pharmaceutical Industries had a return on equity of 14.27% and a net margin of 46.55%. View Taro Pharmaceutical Industries' Earnings History.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, May 16th 2019. View Earnings Estimates for Taro Pharmaceutical Industries.

What price target have analysts set for TARO?

1 brokers have issued 1 year price targets for Taro Pharmaceutical Industries' shares. Their predictions range from $115.00 to $115.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $115.00 in the next year. This suggests a possible upside of 6.6% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.

What is the consensus analysts' recommendation for Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.

What are Wall Street analysts saying about Taro Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Taro Pharmaceutical Industries stock:
  • 1. According to Zacks Investment Research, "Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals. " (2/8/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a price objective of $115 per share, based on a forward EPS multiple of 15.5x applied to our current fiscal 2019 EPS forecast of $7.40 per share." (12/10/2018)

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

News headlines about TARO stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a news impact score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the immediate future.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a decline in short interest during the month of February. As of February 15th, there was short interest totalling 253,806 shares, a decline of 56.2% from the January 31st total of 579,649 shares. Based on an average daily trading volume, of 88,026 shares, the days-to-cover ratio is currently 2.9 days. Currently, 2.7% of the company's stock are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Who are some of Taro Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), Skyworks Solutions (SWKS), Neurocrine Biosciences (NBIX), Netflix (NFLX), Thermo Fisher Scientific (TMO), Celgene (CELG) and Jazz Pharmaceuticals (jazz).

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Uday V. Baldota, CEO & Director (Age 49)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
  • Mr. Itzik Baruch, VP of Technical Services (Age 56)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (1.63%), Acadian Asset Management LLC (0.78%), Dimensional Fund Advisors LP (0.76%), Dimensional Fund Advisors LP (0.76%), Norges Bank (0.62%) and Freestone Capital Holdings LLC (0.25%).

Which major investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including Freestone Capital Holdings LLC, Fort L.P., Northern Trust Corp, D. E. Shaw & Co. Inc., Canada Pension Plan Investment Board, FMR LLC, Barclays PLC and Boston Partners.

Which major investors are buying Taro Pharmaceutical Industries stock?

TARO stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Actinver Wealth Management Inc., Acadian Asset Management LLC, Bank of New York Mellon Corp, Brandes Investment Partners LP and Hsbc Holdings PLC.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $107.83.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $4.25 billion and generates $661.91 million in revenue each year. The company earns $211.15 million in net income (profit) each year or $6.18 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,490 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is http://www.taro.com.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]


MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  402
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel